Comparison of EGFR with Other Molecular, Demographic and Clinicopathologic Data in Nonsmall Cell Lung Carcinoma: A Study from Tertiary Cancer Centre from Western Part of India

Most of non-small cell lung cancer (NSCLC) is a locally advanced or metastatic stage which is affiliated with constrained therapy option and poor prognosis at appearance. Approximately 30% of NSCLC tumors harbor a mutation in the epidermal growth factor receptor (EGFR) gene, with geographical variation in rates reported to be highest in Asia (38%) and lowest in Europe (14%). With tumor molecular genetics at the forefront of precision medicine, subclassification of NSCLC based on EGFR mutation status has been paramount for predicting response to EGFR targeted therapies in unresectable advanced and metastatic disease. Patients / Materials & methods: 100 cases of lung carcinoma were retrospectively studied from October 2019 to February 2021. These patients were identified on the basis of biopsy proven non small cell lung carcinoma or metastatic carcinoma in lung biopsy and EGFR detection was present. Results: Of the 100 cases who underwent the EGFR detection method, Total no of cases in which EGFR mutation is present is 17 (34%) and total no of EGFR wild type cases is 32 (64%) This study supports the finding of increased metastatic recurrence in patients with locally advanced EGFR mutated (70.5%) NSCLC undergoing definitive therapy as compared to wild type disease (50%).